Investigational drug · Phase 3
Tertomotide
Also called: GV1001
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Moderate to Severe Alzheimer's Disease, Mild to Moderate Alzheimer's Disease, Progressive Supranuclear Palsy.
Phase 3Last checked: Nov 19, 2026Latest source record: Jun 10, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
3
1 still active
All registered trials
9
Any phase or sponsor naming "Tertomotide"
First trial start
2022
Oct 5, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Tertomotide", any sponsor or status.
Conditions studied
As listed on its trial records.
- Moderate to Severe Alzheimer's Disease
- Mild to Moderate Alzheimer's Disease
- Progressive Supranuclear Palsy
Approved drugs for the same conditions: Alzheimer's disease · Neurology
Largest trials
Live from ClinicalTrials.gov: studies naming "Tertomotide" as an intervention, largest first.
- GV1001 Subcutaneous for the Treatment of Moderate to Severe Alzheimer's Disease(AD)Pivotal-lookingNot yet recruiting
Samsung Pharmaceutical Co., Ltd.Industry
NCT05303701 · 750 participants (planned) · Start Jul 2027 · Primary completion Jan 2028
Drug: GV1001 Placebo; GV1001 1.12mg · For: Moderate to Severe Alzheimer's Disease
- GV1001 Subcutaneous(SC) for the Treatment of Mild to Moderate Alzheimer's Disease (AD)Pivotal-lookingCompleted
GemVax & KaelIndustry
NCT05189210 · 199 participants · Start Oct 5, 2022 · Primary completion Apr 3, 2025
Drug: GV1001 Placebo; GV1001 0.56mg and 1 more · For: Mild to Moderate Alzheimer's Disease
Sites: Adventura, Florida; Greenacres City, Florida; Miami, Florida · 35 sites in all
- A Phase II Clinical Trial to Evaluate the Efficacy and Safety of GV1001 in Patients With BPHPivotal-lookingCompleted
GemVax & KaelIndustry
NCT02855892 · 161 participants · Start Oct 2015 · Primary completion Oct 2016
Drug: GV1001 · For: Benign Prostatic Hyperplasia (BPH)
Sites: Guri-si, South Korea; Seongnam-si, South Korea; Gyeongju, South Korea · 8 sites in all
- A Phase III Study to Assess the Efficacy and Safety of GV1001-Gem/Cap vs Gem/Cap in Pancreatic Cancer PatientsPivotal-lookingStatus unknown
Samsung Pharmaceutical Co., Ltd.Industry
NCT02854072 · 148 participants (planned) · Start Nov 2015 · Primary completion May 2018
Drug: GV1001; Gemcitabine and 1 more · For: Pancreatic Cancer
Sites: Wŏnju, South Korea; Goyang-si, South Korea; Jeju City, South Korea · 16 sites in all
GemVax & KaelIndustry
NCT03184467 · 96 participants · Start Sep 5, 2017 · Primary completion Sep 5, 2019
Drug: Normal Saline 0.9%; GV1001 0.56 mg and 1 more · For: Alzheimer Disease
Sites: Guri-si, South Korea
GemVax & KaelIndustry
NCT05819658 · 78 participants · Start Jun 14, 2023 · Primary completion Oct 11, 2024
Drug: GV1001 Placebo; GV1001 0.56mg and 1 more · For: Progressive Supranuclear Palsy
Sites: Seongnam-si, South Korea; Seoul, South Korea · 5 sites in all
GemVax & KaelIndustry
NCT06235775 · 67 participants · Start Dec 12, 2023 · Primary completion Sep 1, 2025
Drug: GV1001 Placebo; GV1001 1.12mg · For: Progressive Supranuclear Palsy
Sites: Seongnam-si, South Korea; Seoul, South Korea · 5 sites in all
- Evaluation of the Safety, Tolerability and PK Characteristics of GV1001 in Healthy SubjectsCompleted
GemVax & KaelIndustry
NCT06625710 · 59 participants · Start Oct 8, 2024 · Primary completion Aug 25, 2025
Drug: GV1001; Placebo · For: Neuro-Degenerative Disease
Sites: Seoul, South Korea
GemVax & KaelIndustry
NCT03959553 · 0 participants · Start Sep 1, 2019 · Primary completion Aug 31, 2021
Drug: GV1001; Normal saline · For: Moderate Alzheimer's Disease
Newest research
PubMed records naming it or its code names, newest first.
- The telomerase reverse transcriptase-derived peptide GN11 alleviates glycolysis and cellular senescence in the fibrotic kidney by inhibiting the TGF-β1/Smad3/lncRNA Oip5-os1/miR-30c-5p/Rock2 axis.
Yang R, Zhang J, Feng X, et al. · Biochem Pharmacol 2026
- A human telomerase reverse transcriptase-derived peptide GV1001 rescues neurodegeneration in a mouse model of Alzheimer disease.
Lee Y, Nam H, Lee JW, et al. · Exp Mol Med 2026
- GV1001: repurposing a telomerase-derived peptide for neurological therapeutics.
Suk K, Lee WH · Expert Opin Investig Drugs 2026
- GV1001, hTERT Peptide Fragment, Prevents 5-Fluorouracil-Induced Mucositis by Inhibiting Mitochondrial Damages.
Beheshtian C, Chen W, Kim S, et al. · Cells 2026
- GV1001 Reprograms CD47 Immune Checkpoint to Restore Macrophage Antitumor Activity in Oral Squamous Cell Carcinoma.
Chen W, Kim S, Beheshtian C, et al. · Int J Mol Sci 2026
- GV1001 reduces pathological 4R tau and functional deficits in models relevant to progressive supranuclear palsy.
Jang KB, Kang DM, Lee MH, et al. · Sci Rep 2026
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.